Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nesyrgy, are calcium channel blocker and beta‑blocker presented as oral tablets for oral use. They treat hypertension in adult patients. The combination provides complementary vasodilatory effects and reduces cardiac workload, helping to achieve target blood pressure levels.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product quality and responsive technical support.

Nesyrgy, a combination antihypertensive, is indicated for conditions involving elevated blood pressure.

Hypertension: lowers systolic and diastolic blood pressure, helping patients achieve target levels. Essential hypertension: reduces blood pressure in patients with primary hypertension. Isolated systolic hypertension: controls high systolic pressure in older adults.

Nesyrgy may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Peripheral edema - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe hypotension - Bradycardia - Heart block - Allergic reactions such as rash or angioedema

When prescribing Nesyrgy, consider the following precautions.

Blood pressure monitoring: regularly check blood pressure after initiation and dose changes. Cardiac function assessment: evaluate heart rate and ECG in patients with conduction disorders. Hepatic impairment: use with caution and consider dose adjustment. Elderly patients: start at low dose and monitor for orthostatic hypotension. Concomitant beta‑blockers: avoid excessive β‑blockade; adjust therapy as needed. Store at room temperature: keep in original container, protect from moisture and light.

Nesyrgy can interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels of both components. - Simultaneous use with other potent antihypertensives (e.g., clonidine, hydralazine): risk of excessive hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase nebivolol exposure. - Calcium channel blocker antagonists (e.g., diltiazem, verapamil): additive vasodilatory effect. - Diuretics: monitor electrolytes and blood pressure.